Dr. Xiaoyu Liu 刘晓渝
Chief Physician
Breast Cancer Center, Chongqing University Cancer Hospital, Chongqing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Early diagnosis and comprehensive, individualized treatment of breast cancer. Expertise includes breast-conserving surgery, mastectomy, sentinel lymph node biopsy, oncoplastic surgery, and breast reconstruction using latissimus dorsi or rectus abdominis flaps.
Dr. Liu graduated from West China University of Medical Sciences in 1990 and trained at Henri-Mondor Hospital in Paris (1996–1997) in breast cancer multimodal therapy and reconstruction. Since returning, Dr. Liu has worked at Chongqing University Cancer Hospital, focusing on clinical care and research. Dr. Liu introduced ductoscopy in Chongqing in 2002 and co-authored a chapter on breast reconstruction in 2004.
Professional roles
- Deputy Director, Breast Center
- Member, Chongqing Breast Cancer Professional Committee, China Anti-Cancer Association
- Member, Clinical Oncology Pharmacy Collaboration Alliance (10 provinces/municipalities)
- Member, Chinese Society of Clinical Oncology (CSCO)
Name order: in Chinese the family name comes first (Liu Xiaoyu). Papers usually list the name as Xiaoyu Liu or Liu X.
Selected publications
22 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Signal Transduct Target Ther, 2025 (first author): Towards biomarker-driven cancer immunotherapy: the rising of a protein phosphatase regulator. PubMed 41083487
- Front Oncol, 2025 (senior author): Prognostic significance of the pretreatment pan-immune-inflammation value in colorectal cancer patients: an updated meta-analysis. PubMed 40777110
- Eur J Surg Oncol, 2025 (senior author): Comment on "Effects of enteral immunonutrition in laparoscopic versus open resections in colorectal cancer surgery: A meta-analysis of randomized controlled trials". PubMed 40009932
- JHEP Rep, 2024 (first author): PPP1R15A-expressing monocytic MDSCs promote immunosuppressive liver microenvironment in fibrosis-associated hepatocellular carcinoma. PubMed 38882672
- Spectrochim Acta A Mol Biomol Spectrosc, 2020 (first author): Two metal-coordination polymers: Photocatalytic hydrogen production and clinical nursing value on gastric cancer combined with hyperthermic intraperitoneal chemotherapy by inducing induce oxidative stress response. PubMed 32836096
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion